SG91270A1 - Sustained release formulation - Google Patents

Sustained release formulation

Info

Publication number
SG91270A1
SG91270A1 SG200001988A SG200001988A SG91270A1 SG 91270 A1 SG91270 A1 SG 91270A1 SG 200001988 A SG200001988 A SG 200001988A SG 200001988 A SG200001988 A SG 200001988A SG 91270 A1 SG91270 A1 SG 91270A1
Authority
SG
Singapore
Prior art keywords
sustained release
release formulation
active ingredient
carbamazepine
tablet form
Prior art date
Application number
SG200001988A
Inventor
Daniela Licht
Marina Zholkovsky
Roman Kaplan
Michael Friedman
Abraham Yacobi
Yechiel Golander
Dan Moros
Barrie Levitt
Original Assignee
Taro Pharma Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharma Ind filed Critical Taro Pharma Ind
Publication of SG91270A1 publication Critical patent/SG91270A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Abstract

The present invention provides a pharmaceutical preparation in tablet form, where the active ingredient is an anti-epileptic medication, preferably a sustained release formulation, and most preferably a sustained release formulation where the active ingredient is carbamazepine. The product consists of carbamazepine particles coated with a single hydrophobic layer and is in a disintegrating tablet form. <IMAGE>
SG200001988A 1999-04-15 2000-04-07 Sustained release formulation SG91270A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/292,609 US6162466A (en) 1999-04-15 1999-04-15 Sustained release formulation of carbamazepine

Publications (1)

Publication Number Publication Date
SG91270A1 true SG91270A1 (en) 2002-09-17

Family

ID=23125414

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200001988A SG91270A1 (en) 1999-04-15 2000-04-07 Sustained release formulation

Country Status (10)

Country Link
US (1) US6162466A (en)
EP (1) EP1044681B1 (en)
AT (1) ATE290854T1 (en)
AU (1) AU761441B2 (en)
CA (1) CA2303973C (en)
DE (1) DE60018629T2 (en)
ES (1) ES2238982T3 (en)
NZ (1) NZ503772A (en)
SG (1) SG91270A1 (en)
ZA (1) ZA200001852B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US6572889B1 (en) * 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
WO2006009403A1 (en) 2004-07-22 2006-01-26 Amorepacific Corporation Sustained-release preparations containing topiramate and the producing method thereof
JP2008539240A (en) * 2005-04-25 2008-11-13 テバ ファーマシュ−ティカルズ ユーエスエー， インコーポレイテッド Sustained release formulation
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
US7674479B2 (en) * 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
CN101129384B (en) * 2007-09-06 2011-07-20 河南天方药业股份有限公司 Method for preparing carbamazepine sustained-release capsules
WO2009087690A2 (en) * 2008-01-11 2009-07-16 Jubilant Organosys Limited Multiparticulate extended release pharmaceutical composition of carbamazepine and process for manufacturing the same
CN101647784B (en) * 2008-08-15 2012-04-11 北京科信必成医药科技发展有限公司 Carbamazepine sustained-release tablet and preparation method thereof
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08157392A (en) * 1994-12-01 1996-06-18 Kanegafuchi Chem Ind Co Ltd Release control type preparation
US5888545A (en) * 1994-07-01 1999-03-30 Arzneimittelwerk Dresden Gmbh Carbamazepine medicament with retarded active substance release
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
WO2000019984A2 (en) * 1998-10-02 2000-04-13 Röhm Gmbh Coated medicament forms with controlled active substance release

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
JP3116648B2 (en) * 1993-04-13 2000-12-11 株式会社豊田自動織機製作所 Hydraulic control device for cargo handling
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888545A (en) * 1994-07-01 1999-03-30 Arzneimittelwerk Dresden Gmbh Carbamazepine medicament with retarded active substance release
JPH08157392A (en) * 1994-12-01 1996-06-18 Kanegafuchi Chem Ind Co Ltd Release control type preparation
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
WO2000019984A2 (en) * 1998-10-02 2000-04-13 Röhm Gmbh Coated medicament forms with controlled active substance release

Also Published As

Publication number Publication date
DE60018629D1 (en) 2005-04-21
ES2238982T3 (en) 2005-09-16
EP1044681A3 (en) 2002-01-02
CA2303973A1 (en) 2000-10-15
DE60018629T2 (en) 2006-04-13
NZ503772A (en) 2001-06-29
ZA200001852B (en) 2001-02-20
AU2641300A (en) 2000-10-19
US6162466A (en) 2000-12-19
ATE290854T1 (en) 2005-04-15
CA2303973C (en) 2009-12-22
EP1044681B1 (en) 2005-03-16
AU761441B2 (en) 2003-06-05
EP1044681A2 (en) 2000-10-18

Similar Documents

Publication Publication Date Title
SG91270A1 (en) Sustained release formulation
CA2258095A1 (en) Tetrahydrolipstatin containing compositions
CA2451842A1 (en) Chewable product including active ingredient
CA2337046A1 (en) Sustained release pharmaceutical preparation
CA2119253A1 (en) Medication Vehicles Made of Solid Lipid Particles (Solid Lipid Nanospheres-SLN)
WO2003103637A3 (en) Modified release, multiple unit drug delivery systems
HUP9900028A3 (en) Pharmaceutically active quinazoline compounds, their production, use thereof and medicament containing them
MY125662A (en) Pharmaceutical formulations containing darifenacin
CA2307018A1 (en) Osmotic medicament releasing system
AU2002216701A1 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
CA2102630A1 (en) Pharmaceutical compositions of compacted medicaments
AU6909800A (en) Metering and packaging of controlled release medication
CA2208230A1 (en) Controlled release formulation (albuterol)
CA2427815A1 (en) Controlled release hydrocodone formulations
AU8009998A (en) Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance
FR2774288B1 (en) GASTROPROTEGED OMEPRAZOLE MICROGRANULES, PROCESS FOR OBTAINING AND PHARMACEUTICAL PREPARATIONS
DE69519685D1 (en) ORAL MEDICINAL PRODUCT WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES
AU2001280764A1 (en) Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
NZ515644A (en) Oil-core compositions for the sustained release of hydrophobic drugs
AU2002214305A1 (en) Pharmaceutical preparation containing copolyvidone
HUP0003840A2 (en) Controlled released medical formulation
AU1671799A (en) Medicament preparation in the form of a tablet or pellet for acid-labile active substances
WO2002013762A3 (en) Improved solid pharmaceutical dosage formulation of hydrophobic drugs
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
BR9608392A (en) Multiparticulate controlled-release preparation and tablet dosage form.